BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld Asia
Home
» Universal Flu Vaccine Developer Reports Good Phase II Data
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Universal Flu Vaccine Developer Reports Good Phase II Data
Nov. 9, 2011
By
Nuala Moran
No Comments
LONDON – SEEK Ltd. released Phase II results of a challenge trial of its T-cell vaccine FLU-v against influenza, showing healthy volunteers who were vaccinated had less severe symptoms, over a shorter time, than the controls.
BioWorld Asia